AJNN
Academic Journal of Neuropsychiatry and Neuropsychology

Academic Journal of Neuropsychiatry and Neuropsychology (formerly known as the Academic Journal of Neurology and Neurosurgery, e-ISSN:3023-6517), deals with neurology, neurosurgery, psychiatry and clinical psychology accepts articles on these topics. Academic Journal of Neuropsychiatry and Neuropsychology publishes original research articles, review articles, case reports, editorial commentaries, letters to the editor, educational articles, and conference/meeting announcements.

eISSN: 3108-8171
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Letter to the Editor
Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process
Abstract
The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional monoamine (serotonin/norepinephrine) hypothesis. This article reviews the mechanism of action, clinical adverse effects, contraindications, safe administration protocols, and treatment process associated with esketamine, one of these novel therapeutic approaches.

Keywords : Esketamine, treatment-resistant depression, contraindications, safe administration protocol, treatment process

Download Article


1. Janik A, Qiu X, Lane R, et al. esketamine monotherapy in adults with treatment-resistant depression. JAMA Psychiatry. 2025;82(9):877-887. <a href="https://doi.org/10.1001/jamapsychiatry.2025.1317">doi:10.1001/jamapsychiatry.2025.1317</a>
2. Feeney A, Papakostas GI. Pharmacotherapy: ketamine and Esketamine. Psychiatr Clin North Am. 2023;46(2):277-290. <a href="https://doi.org/10.1016/j.psc.2023.02.003">doi:10.1016/j.psc.2023.02.003</a>
3. Castanheira S, Gomes CV, Bicker J, Fortuna A. Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics. Drug Discov Today. 2025; 30(6):104371. <a href="https://doi.org/10.1016/j.drudis.2025.104371">doi:10.1016/j.drudis.2025.104371</a>
4. Buchmayer F, Kasper S. Overcoming the myths of esketamine administration: different and not difficult. Front Psychiatry. 2023;14: 1279657. <a href="https://doi.org/10.3389/fpsyt.2023.1279657">doi:10.3389/fpsyt.2023.1279657</a>
5. Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542-555. <a href="https://doi.org/10.1016/j.jad.2020.09.071">doi:10.1016/j.jad.2020.09.071</a>
6. Orsolini L, Latini R, Pompili M, et al. Understanding the complex of suicide in depression: from research to clinics. Psychiatry Investig. 2020; 17(3):207-221. <a href="https://doi.org/10.30773/PI.2019.0171">doi:10.30773/PI.2019.0171</a>
7. Turkish Medicines and Medical Devices Agency. SPRAVATO 28 mg burun spreyi, çözelti kısa ürün bilgisi. Published 2024. Accessed June 26, 2026.
8. U.S. Food and Drug Administration. Supplement approval: Spravato (esketamine) NDA 211243/S-016. Published January 17, 2025. Accessed June 26, 2026.
9. Wang SM, Kim NY, Na HR, et al. Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis. Clin Psychopharmacol Neurosci. 2021;19(2):341-354. <a href="https://doi.org/10.9758/CPN.2021.19.2.341">doi:10.9758/CPN.2021.19.2.341</a>
10. Kavakbasi E, Rosemann K, Yilmaz M, Berndt H, Baune BT. Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders. Eur Arch Psychiatry Clin Neurosci. 2025;275(8):2379-2387. <a href="https://doi.org/10.1007/S00406-025-02041-9">doi:10.1007/S00406-025-02041-9</a>
11. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383-399. <a href="https://doi.org/10.1176/APPI.AJP.2020.20081251">doi:10.1176/APPI.AJP.2020.20081251</a>
Article available in :
Volume 3, Issue 2, 2026
Page : 46-49
https://doi.org/10.51271/AJNN-0051
Article Information
Received : 10 May 2026
Accepted : 26 Haz 2026
Published : 27 Haz 2026
Corresponding Author :

Abdullah Burak Uygur: Departmant of Psychiatry, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkiye

[email protected]
Citation : Uygur AB, Karakuş K, Çelik Erden S, et al. Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol, and treatment process. Acad J Neuropsychiatry Neuropsychol. 2026;3(2):46-49. doi:10.51271/AJNN-0051

Read: 123
Download : 83
Cited: 0
_Footer